Journal
JOURNAL OF CLINICAL MEDICINE
Volume 11, Issue 11, Pages -Publisher
MDPI
DOI: 10.3390/jcm11113011
Keywords
psoriasis; biologics; therapeutic drug monitoring; lateral flow testing; microsampling
Categories
Funding
- Research Foundation-Flanders (FWO), Belgium [T003218N]
Ask authors/readers for more resources
Therapeutic drug monitoring (TDM) of biologics, including the measurement of drug concentrations and antibodies, is a valuable tool for clinical decision making. In this study, the feasibility and perception of home microsampling for quantification of adalimumab concentrations in psoriasis patients were evaluated. The results showed that lateral flow testing (LFT) and enzyme-linked immunosorbent assay (ELISA) provided consistent measurements. The study demonstrates the potential for TDM implementation for adalimumab using rapid testing and home-based microsampling.
Therapeutic drug monitoring (TDM) of biologics-encompassing the measurement of (trough) concentrations and anti-drug antibodies-is emerging as a valuable tool for clinical decision making. While this strategy needs further validation, attention on its implementation into the clinic is warranted. Rapid testing and easy sampling are key to its implementation. Here, we aimed to evaluate the feasibility and volunteers' perception of home microsampling for quantification of adalimumab (ADM) concentrations in psoriasis patients. In addition, we compared lateral flow testing (LFT) with enzyme-linked immunosorbent assay (ELISA). Patients participating in the SUPRA-A study (clinicaltrials.gov NCT04028713) were asked to participate in a substudy where volumetric absorptive microsampling (VAMS) was performed at home. At three time points, whole blood and corresponding serum samples were collected for ADM measurement using an in-house ELISA. In addition, the patients' perspective on microsampling was evaluated via a questionnaire. LFT-obtained ADM concentrations agreed very well with ELISA results (Pearson's correlation = 0.95 and R-2 = 0.89). ADM concentrations determined in both capillary (via finger prick) and corresponding venous blood VAMS samples correlated strongly with serum concentrations (Pearson's correlation = 0.87). Our preliminary data (n = 7) on rapid testing and home-based microsampling are considered promising with regard to TDM implementation for adalimumab, warranting further research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available